Evidence map›Paper›PMID 42289797›Full record

ArticleStatistics in medicine2026

Design and Analysis of Randomized Clinical Trials With Average Hazard: Practical Guidance and Tools for Implementation.

Miki Horiguchi, Lu Tian, Satoshi Hattori, Hajime Uno

Abstract read
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miki HoriguchiDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9800-1954
Lu TianDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-5893-0169
Satoshi HattoriDepartment of Biomedical Statistics, Osaka University, Suita, Japan.ORCID https://orcid.org/0000-0002-0200-1408
Hajime UnoDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-0622-8471

Funding

Statistical Methods for Optimizing Personalized Treatment SelectionR01HL089778 · NHLBI · STANFORD UNIVERSITY · PI LU TIAN · 2008 to 2026
$4.8M
Survival Data Analysis using general censoring-free incident rateR01GM152499 · NIGMS · DANA-FARBER CANCER INST · PI Hajime Uno · 2024 to 2026
$1.0M
National Heart Lung and Blood Institute R01HL089778NHLBI NIH HHS R01 HL089778NIGMS NIH HHS R01 GM152499NIGMS NIH HHS R01GM152499
6 · The paper itself

Abstract

In most randomized clinical trials evaluating intervention effects on time-to-event outcomes, the log-rank test combined with Cox's hazard ratio (HR) estimation has been the standard test/estimation approach for decades. While this traditional framework offers several advantages, concerns have been raised about HR's limitations as a summary measure of the magnitude of intervention effects. To address these concerns, an alternative approach based on the average hazard (AH) has been proposed. AH is defined as a functional of the survival function of the event time distribution and is interpreted as an average incidence rate over a given time window. Although its theoretical properties and nonparametric inference procedures have already been established, practical guidance for its use in the primary analysis of randomized clinical trials (RCTs) remains limited. In this paper, we address two key aspects critical to the implementation of AH in RCTs: (1) design considerations when the AH-based analysis is used for the primary analysis, and (2) tools for identifying the appropriate timing of the analysis. We provide a framework for study design using AH and introduce a new R package, survAHtools, to support its practical application in RCTs.

Indexed as

Randomized Controlled Trials as TopicResearch DesignComputer SimulationData Interpretation, StatisticalHumansProportional Hazards ModelsSurvival Analysisaverage intensitydata monitoringperson‐time incidence raterestricted mean survival timesample size

Identifiers

PMID42289797
PMCPMC13308804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.